KMT2A and leukemia: Although most of the EZH2 inhibitor clinical trials focus on solid tumors, several trials are investigating its effect on R/R B-NHL.723 The DOT1L inhibitor, pinometostat, also named EPZ5676, has been demonstrated to impair H3K79 methylation and moderately effective in treating MLL-rearranged leukemia.724 Agents targeting histone methylation erasers mainly include LSD1 inhibitors, also named KDM1A inhibitors.